Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reissue Patent
2007-04-25
2011-10-04
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S427000, C514S297000, C514S212010, C514S411000, C546S079000, C546S101000
Reissue Patent
active
RE042802
ABSTRACT:
Compounds of the general formula Iwherein rings B, C, D and E may be present or not and, when present, are combined with A as A+C, A+E, A+B+C, A+B+D, A+B+E, A+C+E, A+B+C+D or A+B+C+D+E, rings B, C and E being aliphatic whereas ring D may be aliphatic or aromatic/heteroaromatic, and wherein X is —(CH2)m—, in which m is an integer 1-3, to form a ring E or, when E is absent, a group R1bound to the nitrogen atom, wherein R1is selected from the group consisting of a hydrogen atom, alkyl or haloalkyl groups of 1 to 3 carbon atoms, cycloalkyl(alkyl) groups of 3 to 5 carbon atoms (i.e. including cyclopropyl, cyclopropylmethyl, cyclobutyl and cyclobutylmethyl) and wherein Y is —(CH2)n—, in which n is an integer 1-3, to form a ring C or when C is absent, a group R2bound to the nitrogen atom, wherein R2is selected from the group consisting of a hydrogen atom, alkyl or haloalkyl groups of 1 to 7 carbon atoms, cycloalkyl(alkyl) groups of 3 to 7 carbon atoms, alkenyl or alkylnyl groups of 3 to 6 carbon atoms, arylalkyl, heteroarylalkyl having 1 to 3 carbon atoms in the alkyl moiety, whilst the aryl/heteroaryl nucleus may be substituted, provided that when rings B, C, D and E are absent NR1R2is different from dimethylamino, N-methyl-N-ethylamino, N-methyl-N-propynyl-amino, N-methyl-N-propylamino and N-hydroxipropyl-N-methylamino, and salts thereof with pharmaceutically acceptable acids or bases are disclosed as well as the use of such compounds for the manufacturing of pharmaceutical compositions for the treatment of Parkinson's disease, psychoses, Huntington's disease, impotence, renal failure, heart failure or hypertension, such pharmaceutical compositions and methods of treating Parkinson's disease and schizophrenia.
REFERENCES:
patent: 3991207 (1976-11-01), Sarges et al.
patent: 4410519 (1983-10-01), Seiler et al.
patent: 4565818 (1986-01-01), Nordmann et al.
patent: 41 14 325 (1992-11-01), None
patent: 5114325 (1992-11-01), None
patent: 0 003 253 (1982-12-01), None
patent: 0 659 430 (1995-06-01), None
patent: 0659430 (1995-06-01), None
patent: 1 179 954 (1959-05-01), None
patent: 2 260 980 (1993-05-01), None
patent: WO 91/00727 (1991-01-01), None
patent: WO 92/18475 (1992-10-01), None
patent: WO 00/06536 (2000-02-01), None
patent: WO 01/28977 (2001-04-01), None
Banker (Modern Pharmaceutics) Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
Niteen Vaidya Diastereomeric crystallization—the classical chiral technology, 2000.
Tommy Litjefors et al., “Pre-and Postsynaptic Dopaminergic Activities of Indolizidine and Quinolizidine Derivatives of 3-(3-Hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP) Further Developments of a Receptor Model”, J. Med. Chem., vol. 33, 1990, pp. 1015-1022, Chart I.
Japanese Office Action, w/ English translation thereof, issued in Japanese Patent Application No. JP 2001-576014 dated Feb. 8, 2011.
Parker et al., “Convergent Synthesis of (±)—Dihydroisocodeine in 11 Steps by the Tandem Radical Cyclization Strategy. A Formal Total Synthesis of (±)—Morphine,” Journal of the American Chemical Society, 1992, 114(2), pp. 9688-9689.
Xu et al., “Single Electron Transfer Promoted Photocyclization Reactions of (Aminoalkyl) cyclohexenones. Mechanistic and Synthetic Features of Processes Involving the Generation and Reasons of Amine Cation and α-Amino Radicals,” Journal of Americal Chemical Society, 1991 113(23), pp. 8863-8878.
Grewe et al., “Heterocyclische Spiroverbindungen,” Justus Liebigs Annalen der Chemie, 1962, 653, pp. 97-104.
Colonna, “Rapid Efficient Route to 3-Hydroxy-o-phenylenediamine Derivatives and Derived Benzoxazolines,” Journal of the Chemical Society, Chemical Communications, 1975, (3), pp. 71.
Tecle et al., “Alkyl Substituted 3-PPP Derivatives. Synthesis and Biological Investigation,” Journal of Heterocyclic Chemistry, 1989, 26(4), pp. 1125-1128.
Grol et al., “Resolution of 5,6-Dihydroxy-2-(N,N-di-n-propylamino) tetralin in Relation to the Structural and Stereochemical Requirements for Centrally Acting Dopamine Agonists,” Journal of Medicinal Chemistry, 1985, vol. 28, No. 5, pp. 679-683.
Bøgesø et al., “Indolizidine and Quinolizidine Derivatives of the Dopamine Autoreceptor Agonist 3-(3-Hydroxyphenyl)-N-n-propylpiperidine (3-PPP),” Journal of Medicinal Chemistry, 1987, vol. 30, No. 1, pp. 142-150.
Klaus P. Bogeso et al., “Indolizidine and Quinolizidine Derivatives of the Dopamine Autoreceptor Agonist 3-(3-Hydroxyphenyl)-N-n-propylpideridine (3-PPP)”, J. Med. Chem., vol. 30, 1987, pp. 142-150, Figure 1.
Cor J. Grol et al., “Resolution of 5,6-Dihyroxy-2-(N,N-di-n-propylamino)tetralin in Relation to the Structural and Stereochemical Requirements for Centrally Acting Dopamine Agonists”, J. Med. Chem., vol. 28, 1985, pp. 679-683, scheme 1.
Dijkstra Durk
Venhuis Bastiaan Johan
Wikström Hâkan Vilheim
Desai Rita
H. Lundbeck A/S
McDermott Will & Emery LLP
LandOfFree
Phenylethylamines and condensed rings variants as prodrugs... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenylethylamines and condensed rings variants as prodrugs..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenylethylamines and condensed rings variants as prodrugs... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4289246